Fig. 7.

ISRIB exerted synergistic roles with circRNA-CREIT in improving chemosensitivity of TNBC cells. A Chemosensitivity to DOX of MDA-MB-231 cells treated with circRNA-CREIT, ISRIB alone or in combination. Cell viability was detected with MTT assays. The IC50 and the 95% CI of cells with different treatments are shown. B Chemosensitivity to doxorubicin of MDA-MB-231 cells treated with sh-circRNA-CREIT, ISRIB alone or in combination was detected by MTT assays. The IC50 and the 95% CI of cells with different treatments are shown. C, D Colony formation assays showed the synergistic roles of circRNA-CREIT and ISRIB in increasing cell chemosensitivity. E A schematic diagram indicating the experimental process of constructing the subcutaneous xenograft model and drug administration in female nude mice. F Images of xenograft tumors after the indicated treatment. Scale bars = 10 mm. G Growth curves and relative weights of the xenograft tumors in the four groups. The group treated with DMSO was used as a control. H IHC staining for Ki67 and cleaved caspase-3 expression in the xenograft tumors of different groups. Scale bars = 100 μm. Three independent experiments were conducted for each result. *p < 0.05; **p < 0.01, ***p < 0.001 compared with the controls